What is MicroOptx?
MicroOptx is dedicated to the development and commercialization of a novel platform technology designed to shunt aqueous humor to the surface of the eye. The company's primary objective is to create a safe and effective treatment for glaucoma by normalizing intraocular pressure, thereby halting the progression of blindness for a majority of patients. The company has projected European market approval for 2021 and U.S. and Canada market approval for 2022, indicating a critical phase of regulatory advancement.
How much funding has MicroOptx raised?
MicroOptx has raised a total of $3.6M across 2 funding rounds:
Private Equity
$2.2M
Debt
$1.4M
Private Equity (2015): $2.2M, investors not publicly disclosed
Debt (2017): $1.4M, investors not publicly disclosed
What's next for MicroOptx?
With substantial enterprise-level funding and a recent strategic investment, MicroOptx is poised to advance its commercialization efforts. The company's focus on achieving market approvals in key regions like Europe, the U.S., and Canada suggests a strategic push towards global market penetration. This capital infusion is expected to fuel the final stages of product development, regulatory submissions, and the initial rollout of its innovative glaucoma treatment, positioning MicroOptx as a significant player in the ophthalmic medical technology sector.
See full MicroOptx company page
